Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12968193 | 1.00 | HSD11B1 (0.50) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL5274231 | 0.91 | HSD11B1 (0.46) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL5270661 | 0.90 | HSD11B1 (0.51) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL1657796 | 0.88 | HSD11B1 (0.49) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL8089481 | 0.86 | HSD11B1 (0.52) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL13216951 | 0.85 | HSD11B1 (0.52) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL8081744 | 0.85 | HSD11B1 (0.52) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL12958841 | 0.80 | HRH3 (0.38) | HRH3STSMAPTESR1LMNA | |
| SCHEMBL5273029 | 0.79 | HSD11B1 (0.55) | HSD11B1HRH3STSMAPTESR1 | |
| SCHEMBL1656552 | 0.76 | HSD11B1 (0.53) | HSD11B1HRH3STSMAPTESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252773-A1 | Method and composition for inhibiting cell proliferation and angiogenesis | SRI INTERNATIONAL | 2012-10-04 | — | — | US | disclosed |
| EP-1877061-B1 | METHOD AND COMPOSITION FOR INHIBITING CELL PROLIFERATION AND ANGIOGENESIS | STANFORD RES INST INT (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2305694-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | SRI International (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1877061-A4 | METHOD AND COMPOSITION FOR INHIBITING CELL PROLIFERATION AND ANGIOGENESIS | STANFORD RES INST INT (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1310509-B1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | STANFORD RES INST INT (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1877061-A2 | METHOD AND COMPOSITION FOR INHIBITING CELL PROLIFERATION AND ANGIOGENESIS | Sri International (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1847548-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006113842-A2 | METHOD AND COMPOSITION FOR INHIBITING CELL PROLIFERATION AND ANGIOGENESIS | SRI INTERNATIONAL (US) | 2006-10-26 | — | — | WO | disclosed |
| US-6747018-B2 | TREATMENT OF ESTROGEN-DEPENDENT DISORDERS; PREFERRED COMPOUNDS HAVE 1,3,5-ESTRATRIENE NUCLEUS, AND ARE SUBSTITUTED AT C-17 OR C-11 WITH MOLECULAR MOIETY WHICH RENDERS COMPOUNDS EFFECTIVE TO BLOCK BINDING OF ESTROGEN TO ITS RECEPTOR | SRI INTERNATIONAL | 2004-06-08 | — | — | US | disclosed |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2003-08-14 | — | — | US | disclosed |
| EP-1310509-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6548491-B2 | For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated | SRI INTERNATIONAL | 2003-04-15 | — | — | US | disclosed |
| US-6503896-B1 | 17-Desoxy-1,3,5-estratriene derivatives; postmenopause, osteoporosis, central nervous system disorders; anticarcinogenic and hypotensive agents | SRI INTERNATIONAL | 2003-01-07 | — | — | US | disclosed |
| US-6455517-B1 | FOR THERAPY OF CONDITIONS OR DISEASES THAT ARE ESTROGEN-DEPENDENT, I.E., ARE ESTROGEN-INDUCED OR ESTROGEN-STIMULATED | SRI INTERNATIONAL | 2002-09-24 | — | — | US | disclosed |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-6281205-B1 | 1,3,5(10)-ESTRATRIENE NUCLEUS, SUBSTITUTED AT THE C-17 POSITION WITH AN AMINE AND ETHER-CONTAINING GROUP | SRI INTERNATIONAL | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | HSD11B1 24/4885HRH3 2058/4885STS 597/4885 |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | HSD11B1 22/4885HRH3 2248/4885STS 559/4885 |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | HSD11B1 22/4885HRH3 2248/4885STS 559/4885 |
| US-20120252773-A1 | Method and composition for inhibiting cell proliferation and angiogenesis | HIF1A, HIF1AN, MKI67 | HSD11B1 155/4885HRH3 1219/4885STS 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.